MTS Medication Technologies (AMEX:MPP) today announced results for the second quarter and six months ended September 30, 2004. The results are presented on both a pro forma basis and in accordance with Generally Accepted Accounting Principals (GAAP). The pro forma results shown in this press release eliminate, from the results of operations, certain non-recurring items that are included in the GAAP results. These items include costs associated with the early repayment of subordinated debt, a restricted stock grant and the relocation of the Company’s headquarters, which are discussed in more detail below.
